Literature DB >> 7705389

Cholesterol biosynthesis in dermal fibroblasts from patients with metabolic disorders of peroxisomal origin.

E Malle1, K Oettl, W Sattler, G Hoefler, G M Kostner.   

Abstract

As peroxisomes possess some of the integral enzymes for cholesterol biosynthesis, the role of these organelles in cholesterol formation was studied in dermal fibroblasts with three types of peroxisomal defect: group I, characterized by the absence of intact peroxisomes (neonatal adrenoleukodystrophy, cerebrohepatorenal syndrome of Zellweger); group II, showing impaired activity of a single peroxisomal enzyme (X-linked adrenoleukodystrophy, adrenomyeloneuropathy); and group III, defective in more than one peroxisomal enzyme (rhizomelic chondrodysplasia punctata). Cells were incubated with three different radioactive precursors, namely [14C]-octanoate, [14C]-acetate, and [3H]-mevalonate, and incorporation of these radiolabels into cholesterol was determined. All fibroblasts with peroxisomal defects were able to form cholesterol at concentrations comparable or higher than those in controls dependent on the radioactive substrate. Binding properties (KD) and bmax values) of LDL to fibroblasts with peroxisomal defects and downregulation of intracellular cholesterol biosynthesis were similar to those found in fibroblasts from normolipidaemic controls, but different to those observed in LDL-receptor negative fibroblasts. As our studies revealed that cholesterol biosynthesis is not impaired in fibroblasts from patients with metabolic disorders of peroxisomal origin, we conclude that peroxisomes play little or no role in the pathway of cholesterol synthesis beyond mevalonate. In earlier steps of the cholesterol synthesis pathway, peroxisomal and mitochondrial defects in parallel may alter cholesterol synthesis indirectly.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705389     DOI: 10.1111/j.1365-2362.1995.tb01527.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  Cholesterol biosynthesis in Zellweger syndrome: normal activity of mevalonate kinase, mevalonate-5'-pyrophosphate decarboxylase and IPP-isomerase in patients' fibroblasts but deficient mevalonate kinase activity in liver.

Authors:  R J Wanders; G J Romeijn
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

2.  Smith-Lemli-Opitz syndrome: deficient delta 7-reductase activity in cultured skin fibroblasts and chorionic villus fibroblasts and its application to pre- and postnatal detection.

Authors:  R J Wanders; G J Romeijn; F Wijburg; R C Hennekam; J de Jong; R A Wevers; G Dacremont
Journal:  J Inherit Metab Dis       Date:  1997-07       Impact factor: 4.982

3.  The lipidation status of acute-phase protein serum amyloid A determines cholesterol mobilization via scavenger receptor class B, type I.

Authors:  Gunther Marsche; Sasa Frank; John G Raynes; Karen F Kozarsky; Wolfgang Sattler; Ernst Malle
Journal:  Biochem J       Date:  2007-02-15       Impact factor: 3.857

4.  Disturbed cholesterol homeostasis in a peroxisome-deficient PEX2 knockout mouse model.

Authors:  Werner J Kovacs; Janis E Shackelford; Khanichi N Tape; Michael J Richards; Phyllis L Faust; Steven J Fliesler; Skaidrite K Krisans
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

5.  Modulation of Coenzyme Q10 content and oxidative status in human dermal fibroblasts using HMG-CoA reductase inhibitor over a broad range of concentrations. From mitohormesis to mitochondrial dysfunction and accelerated aging.

Authors:  Fabio Marcheggiani; Ilenia Cirilli; Patrick Orlando; Sonia Silvestri; Alexandra Vogelsang; Anja Knott; Thomas Blatt; Julia M Weise; Luca Tiano
Journal:  Aging (Albany NY)       Date:  2019-05-10       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.